ERBB2 and breast cancer: Acting on EGFR and HER2 tyrosine kinase domains, lapatinib decreased the phosphorylation of 95HER2 and inactivated the downstream Akt and MAPK pathways, inhibiting trastuzumab-resistant tumor growth in mice with HER2+ BC [108,170].